Literatur
-
1
Bhole V, Choi J W, Kim S W, de Vera M, Choi H.
Serum uric acid levels and the risk of type 2 diabetes.
Am
J Med.
2010;
123
957-961
-
2
Filippatos G S, Ahmed M I, Gladden J D. et al .
Hyperuricaemia, chronic
kidney disease, and outcomes in heart failure: potential mechanistic
insights from epidemiological data.
Eur Heart J.
2011;
32
712-720
-
3
Fravel M A, Ernst M E.
Management of
gout in the older adult.
Am J Geriatr Pharmacother.
2011;
9
271-285
-
4
Goicoechea M, de Vinuesa S G, Verdalles U. et al .
Effect of allopurinol in
chronic kidney disease progression and cardiovascular risk.
Clin
J Am Soc Nephrol.
2010;
5
1388-1393
-
5
Kao M P, Ang D S. et al .
Allopurinol
benefits left ventricular mass and endothelial dysfunction in chronic
kidney disease.
J Am Soc Nephrol.
2011;
22
1382-1389
-
6
Kielstein J T, Schmidt B MW.
High-dose
allopurinol in patients with stable angina pectoris.
Lancet.
2010;
376
1298-1299
-
7
Martin W J, Walton M, Harper J.
Resident macrophages initiating and driving inflammation in
a monosodium urate monohydrate crystal-induced murin peritoneal
model of acute gout.
Arthritis Rheum.
2009;
60
281-289
-
8
Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J.
Gout associated uric acid crystals activate the NALP3 inflammasome.
Nature.
2006;
440
237-241
-
9
Richette P, Ottaviani S, Bardin T.
New therapeutic options for gout.
Presse Med.
2011;
40
844-849
-
10
Schlesinger N, Mysler E, Lin H -Y. et al .
Canakinumab reduces the risk of acute gouty
arthritis flares during initiation of allopurinol treatment.
Ann
Rheum Dis.
2011;
70
1264-1271
-
11
So A, De Meulemeester M, Pikhlak A, Yücel A E, Richard D, Murphy V, Sallstig P, Schlesinger N.
Canakinumab
for the treatment of acute flares in difficult-to-treat gouty arthritis.
Arthritis Rheum.
2010;
62
3064-3076
-
12
Wen C P, David C heng TY, Chan H T. et al .
Is high serum uric acid
a risk marker or a target for treatment?.
Am J Kidney Dis.
2010;
56
273-288
-
13
Whelton A, Macdonald P A, Zhao L, Hunt B, Gunawardhana L.
Renal function in gout: long-term treatment effects of febuxostat.
J Clin Rheumatol.
2011;
17
7-13
-
14
Zhang W, Doherty M, Bardin T. et
al .
EULAR evidence based recommendations for gout. Part
II: Management.
Ann Rheum Dis.
2006;
65:1
312-324
PD Dr. med. Annette D. Wagner
Oberärztin, Vaskulitisambulanz
Spezialambulanz „Seltene entzündliche Systemerkrankungen
mit Nierenbeteiligung“,
Klinik für Nieren-
und Hochdruckerkrankungen
Medizinische Hochschule Hannover
Carl-Neuberg-Str. 1
30625 Hannover
Phone: 0511/532-3745
Fax: 0511/532-8108
